Pharma News

1 May 2024

IIT Bombay unveils 10x GMP facility for pharma companies

IIT Bombay unveils the nations first of its kind GMP facility at any academic institution The 10X GMP Facility at IIT Bombay is the first-of- its- kind in India and will help to manufacture products for human trials. This facility will encourage researchers to manufacture breakthrough products in healthcare which are 10 times cheaper or better or faster than anything currently available.

1 May 2024

Lilly Q1 2024 increased by 26 percent driven by Mounjaro, Zepbound, Verzenio and Jardiance

In Q1 2024, worldwide revenue was USD 8.77 billion, an increase of 26 percent compared with Q1 2023, driven by increases of 16 percent in volume and 10 percent due to higher realized prices. The volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio and Jardiance, partially offset by declines in Trulicity.

1 May 2024

Sanofi has launched GLP-1 drug in India

Soliqua is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.

1 May 2024

Denmark to restrict Ozempic and other GLP-1 drugs for Diabetes

Denmark rationalised cheaper diabetic medicines and restricted GLP-1 analogues. The so-called GLP-1 analogues, which include is known under the product names Ozempic, Trulicity, Rybelsus and Victoza, is significantly more expensive than other types of diabetes medication (so-called DPP-4 inhibitors, SGLT-2 inhibitors, beta-cell stimulants and metformin)

30 April 2024

ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

ONO Pharmaceutical, Co., Ltd and Deciphera Pharmaceuticals, Inc. announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for USD 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO.

30 April 2024

FDA approves first drug for WHIM syndrome

WHIM syndrome is a rare genetic disease that causes the body’s immune system to not function properly. WHIM syndrome reduces the number of mature neutrophils and lymphocytes (types of white blood cells important in fighting infection) circulating within the body. It is estimated to occur in about 1 in 5 million live births. Approximately 60 cases have been reported in the medical literature.

30 April 2024

Lower Dose of Mpox Vaccine Is Safe and Generates Six-Week Antibody Response Equivalent to Standard Regimen

A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to findings presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Barcelona. The results suggest that antibody responses contributed to the effectiveness of dose-sparing mpox vaccine regimens used during the 2022 U.S. outbreak.

30 April 2024

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Sandoz received FDA approval for the first and only denosumab biosimilars, Jubbonti and Wyost, on March 5, 2024. Jubbonti and Wyost are interchangeable with and approved by FDA for all indications of reference medicines Prolia and Xgeva. They have the same dosage form, route of administration, dosing regimen and presentation as the respective reference medicines.

29 April 2024

Physical activity in nature helps prevent several diseases, including depression and type 2 diabetes

Physical activity in natural environments prevent almost 13,000 cases of non-communicable diseases a year in England and save treatment costs of more than 100m pound, new research from the University of Exeter has found.